nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—EIF2AK1—pharynx cancer	0.687	0.865	CbGaD
Bosutinib—EGFR—pharynx cancer	0.107	0.135	CbGaD
Bosutinib—Vandetanib—EGFR—pharynx cancer	0.00186	0.513	CrCbGaD
Bosutinib—Gefitinib—EGFR—pharynx cancer	0.00177	0.487	CrCbGaD
Bosutinib—BTK—spinal cord—pharynx cancer	0.00027	0.00247	CbGeAlD
Bosutinib—TAOK3—parotid gland—pharynx cancer	0.000269	0.00246	CbGeAlD
Bosutinib—MERTK—lymphoid tissue—pharynx cancer	0.000269	0.00246	CbGeAlD
Bosutinib—CSNK1E—trachea—pharynx cancer	0.000268	0.00245	CbGeAlD
Bosutinib—MAP4K4—lymphoid tissue—pharynx cancer	0.000264	0.00241	CbGeAlD
Bosutinib—IRAK4—trachea—pharynx cancer	0.000264	0.00241	CbGeAlD
Bosutinib—BCR—lymphoid tissue—pharynx cancer	0.000262	0.0024	CbGeAlD
Bosutinib—YES1—saliva-secreting gland—pharynx cancer	0.000261	0.00239	CbGeAlD
Bosutinib—STK4—head—pharynx cancer	0.000261	0.00239	CbGeAlD
Bosutinib—EPHA4—trachea—pharynx cancer	0.000261	0.00239	CbGeAlD
Bosutinib—ERBB4—spinal cord—pharynx cancer	0.000259	0.00237	CbGeAlD
Bosutinib—ERBB3—trachea—pharynx cancer	0.000258	0.00236	CbGeAlD
Bosutinib—TAOK3—saliva-secreting gland—pharynx cancer	0.000258	0.00236	CbGeAlD
Bosutinib—EPHB4—epithelium—pharynx cancer	0.000258	0.00236	CbGeAlD
Bosutinib—CAMK1D—head—pharynx cancer	0.000258	0.00236	CbGeAlD
Bosutinib—ULK3—trachea—pharynx cancer	0.000258	0.00236	CbGeAlD
Bosutinib—TLK1—lymph node—pharynx cancer	0.000257	0.00235	CbGeAlD
Bosutinib—PDGFRB—neck—pharynx cancer	0.000257	0.00235	CbGeAlD
Bosutinib—MAP2K1—lymphoid tissue—pharynx cancer	0.000255	0.00233	CbGeAlD
Bosutinib—STK24—head—pharynx cancer	0.000255	0.00233	CbGeAlD
Bosutinib—PRKCQ—lymph node—pharynx cancer	0.000254	0.00232	CbGeAlD
Bosutinib—MAP3K7—trachea—pharynx cancer	0.000253	0.00232	CbGeAlD
Bosutinib—CSK—lymphoid tissue—pharynx cancer	0.000253	0.00232	CbGeAlD
Bosutinib—EPHA2—epithelium—pharynx cancer	0.000253	0.00231	CbGeAlD
Bosutinib—TAOK3—brainstem—pharynx cancer	0.000253	0.00231	CbGeAlD
Bosutinib—CSNK1A1—lymphoid tissue—pharynx cancer	0.000252	0.0023	CbGeAlD
Bosutinib—PTK2—trachea—pharynx cancer	0.000251	0.00229	CbGeAlD
Bosutinib—TBK1—trachea—pharynx cancer	0.000251	0.00229	CbGeAlD
Bosutinib—HCK—lymphoid tissue—pharynx cancer	0.00025	0.00229	CbGeAlD
Bosutinib—CLK1—lymphoid tissue—pharynx cancer	0.00025	0.00229	CbGeAlD
Bosutinib—EPHB3—spinal cord—pharynx cancer	0.000247	0.00226	CbGeAlD
Bosutinib—FER—head—pharynx cancer	0.000247	0.00225	CbGeAlD
Bosutinib—TYRO3—head—pharynx cancer	0.000247	0.00225	CbGeAlD
Bosutinib—ALK—head—pharynx cancer	0.000247	0.00225	CbGeAlD
Bosutinib—EPHA5—head—pharynx cancer	0.000247	0.00225	CbGeAlD
Bosutinib—LYN—head—pharynx cancer	0.000245	0.00224	CbGeAlD
Bosutinib—MAP3K19—head—pharynx cancer	0.000242	0.00221	CbGeAlD
Bosutinib—MAP2K5—parotid gland—pharynx cancer	0.000241	0.00221	CbGeAlD
Bosutinib—RPS6KB1—trachea—pharynx cancer	0.000241	0.0022	CbGeAlD
Bosutinib—LCK—trachea—pharynx cancer	0.00024	0.00219	CbGeAlD
Bosutinib—MAP4K4—spinal cord—pharynx cancer	0.000239	0.00219	CbGeAlD
Bosutinib—AXL—trachea—pharynx cancer	0.000239	0.00218	CbGeAlD
Bosutinib—DSTYK—lymph node—pharynx cancer	0.000238	0.00218	CbGeAlD
Bosutinib—CLK3—lymph node—pharynx cancer	0.000238	0.00218	CbGeAlD
Bosutinib—BMX—lymph node—pharynx cancer	0.000238	0.00218	CbGeAlD
Bosutinib—BCR—spinal cord—pharynx cancer	0.000238	0.00217	CbGeAlD
Bosutinib—PTK2B—lymphoid tissue—pharynx cancer	0.000237	0.00217	CbGeAlD
Bosutinib—TNK2—head—pharynx cancer	0.000237	0.00217	CbGeAlD
Bosutinib—MAP3K12—spinal cord—pharynx cancer	0.000236	0.00216	CbGeAlD
Bosutinib—BLK—lymph node—pharynx cancer	0.000235	0.00215	CbGeAlD
Bosutinib—CASK—lymph node—pharynx cancer	0.000233	0.00213	CbGeAlD
Bosutinib—PHKG1—lymph node—pharynx cancer	0.000233	0.00213	CbGeAlD
Bosutinib—MAP2K5—saliva-secreting gland—pharynx cancer	0.000231	0.00211	CbGeAlD
Bosutinib—MAP2K1—spinal cord—pharynx cancer	0.000231	0.00211	CbGeAlD
Bosutinib—ERBB4—head—pharynx cancer	0.00023	0.00211	CbGeAlD
Bosutinib—STK3—head—pharynx cancer	0.00023	0.00211	CbGeAlD
Bosutinib—EIF2AK1—lymph node—pharynx cancer	0.00023	0.00211	CbGeAlD
Bosutinib—SLK—trachea—pharynx cancer	0.00023	0.0021	CbGeAlD
Bosutinib—CSK—spinal cord—pharynx cancer	0.00023	0.0021	CbGeAlD
Bosutinib—SIK1—lymphoid tissue—pharynx cancer	0.00023	0.0021	CbGeAlD
Bosutinib—IRAK4—lymphoid tissue—pharynx cancer	0.00023	0.0021	CbGeAlD
Bosutinib—CSNK1A1—spinal cord—pharynx cancer	0.000228	0.00209	CbGeAlD
Bosutinib—EPHB4—trachea—pharynx cancer	0.000228	0.00208	CbGeAlD
Bosutinib—ROCK1—head—pharynx cancer	0.000227	0.00208	CbGeAlD
Bosutinib—HCK—spinal cord—pharynx cancer	0.000227	0.00207	CbGeAlD
Bosutinib—CLK1—spinal cord—pharynx cancer	0.000227	0.00207	CbGeAlD
Bosutinib—MAP2K5—brainstem—pharynx cancer	0.000227	0.00207	CbGeAlD
Bosutinib—TXK—lymph node—pharynx cancer	0.000225	0.00206	CbGeAlD
Bosutinib—ERBB3—lymphoid tissue—pharynx cancer	0.000225	0.00206	CbGeAlD
Bosutinib—MAP2K2—lymphoid tissue—pharynx cancer	0.000224	0.00205	CbGeAlD
Bosutinib—EPHA2—trachea—pharynx cancer	0.000224	0.00205	CbGeAlD
Bosutinib—FYN—trachea—pharynx cancer	0.000223	0.00204	CbGeAlD
Bosutinib—FES—lymph node—pharynx cancer	0.000223	0.00204	CbGeAlD
Bosutinib—VRK2—lymph node—pharynx cancer	0.000223	0.00204	CbGeAlD
Bosutinib—MAP3K2—lymphoid tissue—pharynx cancer	0.000223	0.00204	CbGeAlD
Bosutinib—BMP2K—spinal cord—pharynx cancer	0.000222	0.00203	CbGeAlD
Bosutinib—CAMK2G—spinal cord—pharynx cancer	0.000222	0.00203	CbGeAlD
Bosutinib—BMPR2—head—pharynx cancer	0.000221	0.00202	CbGeAlD
Bosutinib—LRRK2—spinal cord—pharynx cancer	0.00022	0.00202	CbGeAlD
Bosutinib—SRC—epithelium—pharynx cancer	0.000219	0.002	CbGeAlD
Bosutinib—STK36—head—pharynx cancer	0.000219	0.002	CbGeAlD
Bosutinib—EPHB3—head—pharynx cancer	0.000219	0.002	CbGeAlD
Bosutinib—TNIK—lymph node—pharynx cancer	0.000219	0.002	CbGeAlD
Bosutinib—SYK—lymph node—pharynx cancer	0.000219	0.002	CbGeAlD
Bosutinib—MAP3K3—trachea—pharynx cancer	0.000218	0.002	CbGeAlD
Bosutinib—MAP4K5—trachea—pharynx cancer	0.000218	0.002	CbGeAlD
Bosutinib—PTK2—lymphoid tissue—pharynx cancer	0.000218	0.002	CbGeAlD
Bosutinib—TBK1—lymphoid tissue—pharynx cancer	0.000218	0.002	CbGeAlD
Bosutinib—CDK2—lymph node—pharynx cancer	0.000217	0.00198	CbGeAlD
Bosutinib—MERTK—head—pharynx cancer	0.000217	0.00198	CbGeAlD
Bosutinib—STK26—lymph node—pharynx cancer	0.000215	0.00196	CbGeAlD
Bosutinib—MAP4K4—head—pharynx cancer	0.000213	0.00194	CbGeAlD
Bosutinib—CSNK1E—spinal cord—pharynx cancer	0.000211	0.00193	CbGeAlD
Bosutinib—BCR—head—pharynx cancer	0.000211	0.00193	CbGeAlD
Bosutinib—RPS6KB1—lymphoid tissue—pharynx cancer	0.00021	0.00192	CbGeAlD
Bosutinib—MAP3K12—head—pharynx cancer	0.00021	0.00192	CbGeAlD
Bosutinib—PDGFRB—parotid gland—pharynx cancer	0.000209	0.00191	CbGeAlD
Bosutinib—FGR—lymphoid tissue—pharynx cancer	0.000209	0.00191	CbGeAlD
Bosutinib—SIK1—spinal cord—pharynx cancer	0.000208	0.0019	CbGeAlD
Bosutinib—IRAK4—spinal cord—pharynx cancer	0.000208	0.0019	CbGeAlD
Bosutinib—AXL—lymphoid tissue—pharynx cancer	0.000208	0.0019	CbGeAlD
Bosutinib—CHEK2—lymph node—pharynx cancer	0.000208	0.0019	CbGeAlD
Bosutinib—WEE1—lymph node—pharynx cancer	0.000206	0.00188	CbGeAlD
Bosutinib—DMPK—lymph node—pharynx cancer	0.000206	0.00188	CbGeAlD
Bosutinib—MAP2K1—head—pharynx cancer	0.000205	0.00188	CbGeAlD
Bosutinib—STK35—head—pharynx cancer	0.000205	0.00188	CbGeAlD
Bosutinib—CSK—head—pharynx cancer	0.000204	0.00187	CbGeAlD
Bosutinib—ERBB3—spinal cord—pharynx cancer	0.000204	0.00186	CbGeAlD
Bosutinib—ULK3—spinal cord—pharynx cancer	0.000203	0.00186	CbGeAlD
Bosutinib—MAP2K2—spinal cord—pharynx cancer	0.000203	0.00186	CbGeAlD
Bosutinib—CSNK1A1—head—pharynx cancer	0.000203	0.00185	CbGeAlD
Bosutinib—YES1—trachea—pharynx cancer	0.000202	0.00184	CbGeAlD
Bosutinib—CLK1—head—pharynx cancer	0.000201	0.00184	CbGeAlD
Bosutinib—HCK—head—pharynx cancer	0.000201	0.00184	CbGeAlD
Bosutinib—MAP3K7—spinal cord—pharynx cancer	0.0002	0.00183	CbGeAlD
Bosutinib—PDGFRB—saliva-secreting gland—pharynx cancer	0.0002	0.00183	CbGeAlD
Bosutinib—TAOK3—trachea—pharynx cancer	0.000199	0.00182	CbGeAlD
Bosutinib—TBK1—spinal cord—pharynx cancer	0.000198	0.00181	CbGeAlD
Bosutinib—PTK2—spinal cord—pharynx cancer	0.000198	0.00181	CbGeAlD
Bosutinib—BMP2K—head—pharynx cancer	0.000198	0.00181	CbGeAlD
Bosutinib—CAMK2G—head—pharynx cancer	0.000198	0.00181	CbGeAlD
Bosutinib—STK25—lymph node—pharynx cancer	0.000197	0.0018	CbGeAlD
Bosutinib—LRRK2—head—pharynx cancer	0.000196	0.00179	CbGeAlD
Bosutinib—EPHA3—lymph node—pharynx cancer	0.000195	0.00178	CbGeAlD
Bosutinib—EPHA2—lymphoid tissue—pharynx cancer	0.000195	0.00178	CbGeAlD
Bosutinib—FYN—lymphoid tissue—pharynx cancer	0.000195	0.00178	CbGeAlD
Bosutinib—PLK2—lymph node—pharynx cancer	0.000191	0.00175	CbGeAlD
Bosutinib—PTK2B—head—pharynx cancer	0.000191	0.00175	CbGeAlD
Bosutinib—RPS6KB1—spinal cord—pharynx cancer	0.00019	0.00174	CbGeAlD
Bosutinib—MAP4K5—lymphoid tissue—pharynx cancer	0.00019	0.00174	CbGeAlD
Bosutinib—SIK3—lymph node—pharynx cancer	0.00019	0.00174	CbGeAlD
Bosutinib—AXL—spinal cord—pharynx cancer	0.000188	0.00172	CbGeAlD
Bosutinib—CSNK1E—head—pharynx cancer	0.000188	0.00172	CbGeAlD
Bosutinib—ABL1—parotid gland—pharynx cancer	0.000186	0.0017	CbGeAlD
Bosutinib—SIK1—head—pharynx cancer	0.000185	0.00169	CbGeAlD
Bosutinib—IRAK4—head—pharynx cancer	0.000185	0.00169	CbGeAlD
Bosutinib—EPHA4—head—pharynx cancer	0.000183	0.00167	CbGeAlD
Bosutinib—STK4—lymph node—pharynx cancer	0.000183	0.00167	CbGeAlD
Bosutinib—SLK—spinal cord—pharynx cancer	0.000181	0.00166	CbGeAlD
Bosutinib—ERBB3—head—pharynx cancer	0.000181	0.00166	CbGeAlD
Bosutinib—MAP2K2—head—pharynx cancer	0.000181	0.00165	CbGeAlD
Bosutinib—ULK3—head—pharynx cancer	0.000181	0.00165	CbGeAlD
Bosutinib—CAMK1D—lymph node—pharynx cancer	0.000181	0.00165	CbGeAlD
Bosutinib—EPHB4—spinal cord—pharynx cancer	0.00018	0.00165	CbGeAlD
Bosutinib—MAP3K2—head—pharynx cancer	0.00018	0.00164	CbGeAlD
Bosutinib—STK24—lymph node—pharynx cancer	0.000178	0.00163	CbGeAlD
Bosutinib—ABL1—saliva-secreting gland—pharynx cancer	0.000178	0.00163	CbGeAlD
Bosutinib—MAP2K5—trachea—pharynx cancer	0.000178	0.00163	CbGeAlD
Bosutinib—FYN—spinal cord—pharynx cancer	0.000176	0.00161	CbGeAlD
Bosutinib—TBK1—head—pharynx cancer	0.000176	0.00161	CbGeAlD
Bosutinib—PTK2—head—pharynx cancer	0.000176	0.00161	CbGeAlD
Bosutinib—YES1—lymphoid tissue—pharynx cancer	0.000176	0.0016	CbGeAlD
Bosutinib—ABL1—brainstem—pharynx cancer	0.000175	0.0016	CbGeAlD
Bosutinib—PDGFRB—epithelium—pharynx cancer	0.000175	0.0016	CbGeAlD
Bosutinib—CSF1R—trachea—pharynx cancer	0.000174	0.00159	CbGeAlD
Bosutinib—STK10—lymphoid tissue—pharynx cancer	0.000174	0.00159	CbGeAlD
Bosutinib—TAOK3—lymphoid tissue—pharynx cancer	0.000173	0.00158	CbGeAlD
Bosutinib—FER—lymph node—pharynx cancer	0.000173	0.00158	CbGeAlD
Bosutinib—ALK—lymph node—pharynx cancer	0.000173	0.00158	CbGeAlD
Bosutinib—MAP3K3—spinal cord—pharynx cancer	0.000172	0.00158	CbGeAlD
Bosutinib—MAP4K5—spinal cord—pharynx cancer	0.000172	0.00158	CbGeAlD
Bosutinib—MAP4K1—lymph node—pharynx cancer	0.000169	0.00155	CbGeAlD
Bosutinib—RPS6KB1—head—pharynx cancer	0.000169	0.00155	CbGeAlD
Bosutinib—SRC—lymphoid tissue—pharynx cancer	0.000169	0.00154	CbGeAlD
Bosutinib—BTK—lymph node—pharynx cancer	0.000168	0.00154	CbGeAlD
Bosutinib—FGR—head—pharynx cancer	0.000168	0.00154	CbGeAlD
Bosutinib—AXL—head—pharynx cancer	0.000167	0.00153	CbGeAlD
Bosutinib—TNK2—lymph node—pharynx cancer	0.000166	0.00152	CbGeAlD
Bosutinib—MAP4K2—lymph node—pharynx cancer	0.000164	0.0015	CbGeAlD
Bosutinib—STK3—lymph node—pharynx cancer	0.000161	0.00148	CbGeAlD
Bosutinib—YES1—spinal cord—pharynx cancer	0.000159	0.00146	CbGeAlD
Bosutinib—TAOK3—spinal cord—pharynx cancer	0.000157	0.00144	CbGeAlD
Bosutinib—EPHA2—head—pharynx cancer	0.000157	0.00144	CbGeAlD
Bosutinib—FYN—head—pharynx cancer	0.000157	0.00143	CbGeAlD
Bosutinib—BMPR2—lymph node—pharynx cancer	0.000155	0.00141	CbGeAlD
Bosutinib—PDGFRB—trachea—pharynx cancer	0.000154	0.00141	CbGeAlD
Bosutinib—EPHB3—lymph node—pharynx cancer	0.000153	0.0014	CbGeAlD
Bosutinib—STK36—lymph node—pharynx cancer	0.000153	0.0014	CbGeAlD
Bosutinib—MAP4K5—head—pharynx cancer	0.000153	0.0014	CbGeAlD
Bosutinib—MAP3K3—head—pharynx cancer	0.000153	0.0014	CbGeAlD
Bosutinib—SRC—spinal cord—pharynx cancer	0.000153	0.0014	CbGeAlD
Bosutinib—MERTK—lymph node—pharynx cancer	0.000152	0.00139	CbGeAlD
Bosutinib—CSF1R—lymphoid tissue—pharynx cancer	0.000152	0.00139	CbGeAlD
Bosutinib—MAP4K4—lymph node—pharynx cancer	0.000149	0.00136	CbGeAlD
Bosutinib—BCR—lymph node—pharynx cancer	0.000148	0.00135	CbGeAlD
Bosutinib—NUAK2—lymph node—pharynx cancer	0.000148	0.00135	CbGeAlD
Bosutinib—MAP3K12—lymph node—pharynx cancer	0.000147	0.00134	CbGeAlD
Bosutinib—MAP2K1—lymph node—pharynx cancer	0.000144	0.00132	CbGeAlD
Bosutinib—STK35—lymph node—pharynx cancer	0.000144	0.00132	CbGeAlD
Bosutinib—CSK—lymph node—pharynx cancer	0.000143	0.00131	CbGeAlD
Bosutinib—CSNK1A1—lymph node—pharynx cancer	0.000142	0.0013	CbGeAlD
Bosutinib—YES1—head—pharynx cancer	0.000141	0.00129	CbGeAlD
Bosutinib—HCK—lymph node—pharynx cancer	0.000141	0.00129	CbGeAlD
Bosutinib—CLK1—lymph node—pharynx cancer	0.000141	0.00129	CbGeAlD
Bosutinib—MAP2K5—spinal cord—pharynx cancer	0.000141	0.00129	CbGeAlD
Bosutinib—ABL2—lymph node—pharynx cancer	0.00014	0.00128	CbGeAlD
Bosutinib—STK10—head—pharynx cancer	0.00014	0.00128	CbGeAlD
Bosutinib—TAOK3—head—pharynx cancer	0.00014	0.00128	CbGeAlD
Bosutinib—CAMK2G—lymph node—pharynx cancer	0.000138	0.00127	CbGeAlD
Bosutinib—BMP2K—lymph node—pharynx cancer	0.000138	0.00127	CbGeAlD
Bosutinib—ABL1—trachea—pharynx cancer	0.000138	0.00126	CbGeAlD
Bosutinib—CSF1R—spinal cord—pharynx cancer	0.000137	0.00126	CbGeAlD
Bosutinib—LRRK2—lymph node—pharynx cancer	0.000137	0.00125	CbGeAlD
Bosutinib—EGFR—lymph node—pharynx cancer	0.000137	0.00125	CbGeAlD
Bosutinib—SRC—head—pharynx cancer	0.000136	0.00124	CbGeAlD
Bosutinib—PDGFRB—lymphoid tissue—pharynx cancer	0.000134	0.00123	CbGeAlD
Bosutinib—PTK2B—lymph node—pharynx cancer	0.000134	0.00122	CbGeAlD
Bosutinib—CSNK1E—lymph node—pharynx cancer	0.000132	0.0012	CbGeAlD
Bosutinib—SIK1—lymph node—pharynx cancer	0.00013	0.00118	CbGeAlD
Bosutinib—IRAK4—lymph node—pharynx cancer	0.00013	0.00118	CbGeAlD
Bosutinib—EPHA4—lymph node—pharynx cancer	0.000128	0.00117	CbGeAlD
Bosutinib—ERBB3—lymph node—pharynx cancer	0.000127	0.00116	CbGeAlD
Bosutinib—MAP2K2—lymph node—pharynx cancer	0.000127	0.00116	CbGeAlD
Bosutinib—ULK3—lymph node—pharynx cancer	0.000127	0.00116	CbGeAlD
Bosutinib—MAP3K2—lymph node—pharynx cancer	0.000126	0.00115	CbGeAlD
Bosutinib—MAP2K5—head—pharynx cancer	0.000125	0.00114	CbGeAlD
Bosutinib—MAP3K7—lymph node—pharynx cancer	0.000125	0.00114	CbGeAlD
Bosutinib—PTK2—lymph node—pharynx cancer	0.000123	0.00113	CbGeAlD
Bosutinib—TBK1—lymph node—pharynx cancer	0.000123	0.00113	CbGeAlD
Bosutinib—CSF1R—head—pharynx cancer	0.000122	0.00112	CbGeAlD
Bosutinib—PDGFRB—spinal cord—pharynx cancer	0.000122	0.00111	CbGeAlD
Bosutinib—IRAK1—lymph node—pharynx cancer	0.000121	0.0011	CbGeAlD
Bosutinib—ABL1—lymphoid tissue—pharynx cancer	0.00012	0.0011	CbGeAlD
Bosutinib—RPS6KB1—lymph node—pharynx cancer	0.000118	0.00108	CbGeAlD
Bosutinib—LCK—lymph node—pharynx cancer	0.000118	0.00108	CbGeAlD
Bosutinib—FGR—lymph node—pharynx cancer	0.000118	0.00108	CbGeAlD
Bosutinib—AXL—lymph node—pharynx cancer	0.000117	0.00107	CbGeAlD
Bosutinib—SLK—lymph node—pharynx cancer	0.000113	0.00103	CbGeAlD
Bosutinib—EPHB4—lymph node—pharynx cancer	0.000112	0.00102	CbGeAlD
Bosutinib—EPHA2—lymph node—pharynx cancer	0.00011	0.00101	CbGeAlD
Bosutinib—FYN—lymph node—pharynx cancer	0.00011	0.001	CbGeAlD
Bosutinib—ABL1—spinal cord—pharynx cancer	0.000109	0.000993	CbGeAlD
Bosutinib—PDGFRB—head—pharynx cancer	0.000108	0.000991	CbGeAlD
Bosutinib—MAP4K5—lymph node—pharynx cancer	0.000107	0.00098	CbGeAlD
Bosutinib—MAP3K3—lymph node—pharynx cancer	0.000107	0.00098	CbGeAlD
Bosutinib—YES1—lymph node—pharynx cancer	9.9e-05	0.000905	CbGeAlD
Bosutinib—STK10—lymph node—pharynx cancer	9.81e-05	0.000897	CbGeAlD
Bosutinib—TAOK3—lymph node—pharynx cancer	9.78e-05	0.000894	CbGeAlD
Bosutinib—ABL1—head—pharynx cancer	9.66e-05	0.000883	CbGeAlD
Bosutinib—SRC—lymph node—pharynx cancer	9.53e-05	0.000871	CbGeAlD
Bosutinib—MAP2K5—lymph node—pharynx cancer	8.76e-05	0.000801	CbGeAlD
Bosutinib—CSF1R—lymph node—pharynx cancer	8.55e-05	0.000782	CbGeAlD
Bosutinib—PDGFRB—lymph node—pharynx cancer	7.59e-05	0.000694	CbGeAlD
Bosutinib—ABL1—lymph node—pharynx cancer	6.76e-05	0.000618	CbGeAlD
Bosutinib—ABCB1—epithelium—pharynx cancer	4.84e-05	0.000442	CbGeAlD
Bosutinib—ABCB1—trachea—pharynx cancer	4.28e-05	0.000391	CbGeAlD
Bosutinib—ABCB1—lymphoid tissue—pharynx cancer	3.73e-05	0.000341	CbGeAlD
Bosutinib—ABCB1—spinal cord—pharynx cancer	3.38e-05	0.000309	CbGeAlD
Bosutinib—ABCB1—head—pharynx cancer	3e-05	0.000275	CbGeAlD
Bosutinib—ABCB1—lymph node—pharynx cancer	2.1e-05	0.000192	CbGeAlD
Bosutinib—CDK2—Hemostasis—TP53—pharynx cancer	1.92e-05	0.000208	CbGpPWpGaD
Bosutinib—MAP3K7—Adaptive Immune System—CDH1—pharynx cancer	1.92e-05	0.000208	CbGpPWpGaD
Bosutinib—LCK—B Cell Activation—EGFR—pharynx cancer	1.9e-05	0.000206	CbGpPWpGaD
Bosutinib—BTK—Adaptive Immune System—EGFR—pharynx cancer	1.88e-05	0.000203	CbGpPWpGaD
Bosutinib—EGFR—MAPK Signaling Pathway—TP53—pharynx cancer	1.87e-05	0.000202	CbGpPWpGaD
Bosutinib—IRAK4—Innate Immune System—EGFR—pharynx cancer	1.87e-05	0.000202	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—CDH1—pharynx cancer	1.86e-05	0.000202	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—CCND1—pharynx cancer	1.84e-05	0.000199	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CD79A—pharynx cancer	1.83e-05	0.000198	CbGpPWpGaD
Bosutinib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	1.82e-05	0.000197	CbGpPWpGaD
Bosutinib—SRC—Signaling by FGFR in disease—EGFR—pharynx cancer	1.82e-05	0.000197	CbGpPWpGaD
Bosutinib—ROCK1—Developmental Biology—EGFR—pharynx cancer	1.82e-05	0.000197	CbGpPWpGaD
Bosutinib—CDK2—Cell Cycle—TP53—pharynx cancer	1.81e-05	0.000196	CbGpPWpGaD
Bosutinib—SRC—Signaling by EGFR—EGFR—pharynx cancer	1.81e-05	0.000196	CbGpPWpGaD
Bosutinib—HCK—Innate Immune System—EGFR—pharynx cancer	1.79e-05	0.000194	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by NGF—EGFR—pharynx cancer	1.79e-05	0.000194	CbGpPWpGaD
Bosutinib—SRC—Signaling by EGFR in Cancer—EGFR—pharynx cancer	1.79e-05	0.000194	CbGpPWpGaD
Bosutinib—HCK—Immune System—CDH1—pharynx cancer	1.79e-05	0.000194	CbGpPWpGaD
Bosutinib—BCR—Disease—EGFR—pharynx cancer	1.78e-05	0.000193	CbGpPWpGaD
Bosutinib—SRC—Signaling by PDGF—EGFR—pharynx cancer	1.78e-05	0.000193	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CD79A—pharynx cancer	1.78e-05	0.000193	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling by NGF—EGFR—pharynx cancer	1.75e-05	0.000189	CbGpPWpGaD
Bosutinib—LYN—Immune System—CD79A—pharynx cancer	1.74e-05	0.000189	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—CCND1—pharynx cancer	1.74e-05	0.000189	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CD79A—pharynx cancer	1.74e-05	0.000188	CbGpPWpGaD
Bosutinib—CSNK1E—Cell Cycle—TP53—pharynx cancer	1.72e-05	0.000186	CbGpPWpGaD
Bosutinib—SRC—Focal Adhesion—EGFR—pharynx cancer	1.72e-05	0.000186	CbGpPWpGaD
Bosutinib—STK3—Signaling Pathways—EGFR—pharynx cancer	1.72e-05	0.000186	CbGpPWpGaD
Bosutinib—FYN—Immune System—CD79A—pharynx cancer	1.72e-05	0.000186	CbGpPWpGaD
Bosutinib—SRC—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	1.71e-05	0.000186	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CD79A—pharynx cancer	1.71e-05	0.000185	CbGpPWpGaD
Bosutinib—STK4—Signaling Pathways—TP53—pharynx cancer	1.7e-05	0.000184	CbGpPWpGaD
Bosutinib—ERBB4—Innate Immune System—EGFR—pharynx cancer	1.69e-05	0.000183	CbGpPWpGaD
Bosutinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	1.69e-05	0.000183	CbGpPWpGaD
Bosutinib—FYN—Signaling by NGF—EGFR—pharynx cancer	1.68e-05	0.000182	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—CDH1—pharynx cancer	1.68e-05	0.000182	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by NGF—EGFR—pharynx cancer	1.67e-05	0.000181	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—CCND1—pharynx cancer	1.66e-05	0.00018	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—CDH1—pharynx cancer	1.66e-05	0.00018	CbGpPWpGaD
Bosutinib—IKBKE—Immune System—EGFR—pharynx cancer	1.64e-05	0.000178	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—CDH1—pharynx cancer	1.64e-05	0.000177	CbGpPWpGaD
Bosutinib—ERBB4—Adaptive Immune System—EGFR—pharynx cancer	1.62e-05	0.000176	CbGpPWpGaD
Bosutinib—FGR—Innate Immune System—EGFR—pharynx cancer	1.62e-05	0.000176	CbGpPWpGaD
Bosutinib—MAP2K2—Axon guidance—EGFR—pharynx cancer	1.62e-05	0.000175	CbGpPWpGaD
Bosutinib—BLK—Immune System—CDH1—pharynx cancer	1.62e-05	0.000175	CbGpPWpGaD
Bosutinib—FGR—Immune System—CDH1—pharynx cancer	1.61e-05	0.000175	CbGpPWpGaD
Bosutinib—SRC—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	1.61e-05	0.000175	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—CDH1—pharynx cancer	1.6e-05	0.000173	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—CCND1—pharynx cancer	1.59e-05	0.000173	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—CDH1—pharynx cancer	1.58e-05	0.000171	CbGpPWpGaD
Bosutinib—BLK—Adaptive Immune System—EGFR—pharynx cancer	1.56e-05	0.000169	CbGpPWpGaD
Bosutinib—LYN—Axon guidance—EGFR—pharynx cancer	1.55e-05	0.000168	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling by GPCR—EGFR—pharynx cancer	1.54e-05	0.000167	CbGpPWpGaD
Bosutinib—ABL1—Axon guidance—EGFR—pharynx cancer	1.54e-05	0.000167	CbGpPWpGaD
Bosutinib—FYN—Axon guidance—EGFR—pharynx cancer	1.52e-05	0.000165	CbGpPWpGaD
Bosutinib—MAP2K1—Axon guidance—EGFR—pharynx cancer	1.52e-05	0.000164	CbGpPWpGaD
Bosutinib—FGR—Hemostasis—TP53—pharynx cancer	1.51e-05	0.000164	CbGpPWpGaD
Bosutinib—PTK2—Developmental Biology—EGFR—pharynx cancer	1.5e-05	0.000163	CbGpPWpGaD
Bosutinib—ERBB3—Innate Immune System—EGFR—pharynx cancer	1.49e-05	0.000161	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—CDH1—pharynx cancer	1.48e-05	0.000161	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CD79A—pharynx cancer	1.48e-05	0.000161	CbGpPWpGaD
Bosutinib—YES1—Developmental Biology—EGFR—pharynx cancer	1.48e-05	0.00016	CbGpPWpGaD
Bosutinib—STK3—Signaling Pathways—TP53—pharynx cancer	1.44e-05	0.000156	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—EGFR—pharynx cancer	1.44e-05	0.000156	CbGpPWpGaD
Bosutinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	1.44e-05	0.000156	CbGpPWpGaD
Bosutinib—SYK—Immune System—EGFR—pharynx cancer	1.44e-05	0.000156	CbGpPWpGaD
Bosutinib—ERBB3—Adaptive Immune System—EGFR—pharynx cancer	1.43e-05	0.000155	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD79A—pharynx cancer	1.43e-05	0.000155	CbGpPWpGaD
Bosutinib—PRKCQ—Immune System—EGFR—pharynx cancer	1.41e-05	0.000153	CbGpPWpGaD
Bosutinib—LCK—Signaling by NGF—EGFR—pharynx cancer	1.4e-05	0.000152	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CNDP2—pharynx cancer	1.39e-05	0.000151	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—CCND1—pharynx cancer	1.39e-05	0.000151	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—EGFR—pharynx cancer	1.37e-05	0.000148	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—CDH1—pharynx cancer	1.36e-05	0.000148	CbGpPWpGaD
Bosutinib—CSK—Immune System—EGFR—pharynx cancer	1.36e-05	0.000147	CbGpPWpGaD
Bosutinib—PTK2—Innate Immune System—EGFR—pharynx cancer	1.33e-05	0.000144	CbGpPWpGaD
Bosutinib—PTK2—Immune System—CDH1—pharynx cancer	1.32e-05	0.000143	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—CDH1—pharynx cancer	1.31e-05	0.000142	CbGpPWpGaD
Bosutinib—YES1—Innate Immune System—EGFR—pharynx cancer	1.31e-05	0.000142	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—EGFR—pharynx cancer	1.3e-05	0.000141	CbGpPWpGaD
Bosutinib—YES1—Immune System—CDH1—pharynx cancer	1.3e-05	0.000141	CbGpPWpGaD
Bosutinib—CSNK1A1—Disease—EGFR—pharynx cancer	1.3e-05	0.000141	CbGpPWpGaD
Bosutinib—PRKCQ—Disease—EGFR—pharynx cancer	1.3e-05	0.000141	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	1.29e-05	0.00014	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD79A—pharynx cancer	1.27e-05	0.000137	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ADH7—pharynx cancer	1.26e-05	0.000137	CbGpPWpGaD
Bosutinib—CSK—Disease—EGFR—pharynx cancer	1.26e-05	0.000136	CbGpPWpGaD
Bosutinib—YES1—Adaptive Immune System—EGFR—pharynx cancer	1.26e-05	0.000136	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—EGFR—pharynx cancer	1.25e-05	0.000135	CbGpPWpGaD
Bosutinib—SRC—Signaling by NGF—EGFR—pharynx cancer	1.24e-05	0.000134	CbGpPWpGaD
Bosutinib—IRAK1—Innate Immune System—EGFR—pharynx cancer	1.24e-05	0.000134	CbGpPWpGaD
Bosutinib—PTK2—Hemostasis—TP53—pharynx cancer	1.24e-05	0.000134	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—CDH1—pharynx cancer	1.24e-05	0.000134	CbGpPWpGaD
Bosutinib—TBK1—Immune System—EGFR—pharynx cancer	1.22e-05	0.000132	CbGpPWpGaD
Bosutinib—YES1—Hemostasis—TP53—pharynx cancer	1.22e-05	0.000132	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—TP53—pharynx cancer	1.21e-05	0.000131	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—EGFR—pharynx cancer	1.2e-05	0.00013	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—CCND1—pharynx cancer	1.18e-05	0.000128	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—EGFR—pharynx cancer	1.17e-05	0.000127	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—EGFR—pharynx cancer	1.17e-05	0.000127	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—CDH1—pharynx cancer	1.16e-05	0.000126	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—CDH1—pharynx cancer	1.16e-05	0.000126	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—CCND1—pharynx cancer	1.16e-05	0.000126	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—CCND1—pharynx cancer	1.16e-05	0.000126	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—EGFR—pharynx cancer	1.16e-05	0.000125	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—TP53—pharynx cancer	1.15e-05	0.000124	CbGpPWpGaD
Bosutinib—BTK—Immune System—EGFR—pharynx cancer	1.14e-05	0.000123	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—EGFR—pharynx cancer	1.12e-05	0.000122	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—CCND1—pharynx cancer	1.12e-05	0.000122	CbGpPWpGaD
Bosutinib—MAP3K7—Adaptive Immune System—EGFR—pharynx cancer	1.12e-05	0.000122	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ADH1B—pharynx cancer	1.11e-05	0.00012	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—EGFR—pharynx cancer	1.1e-05	0.00012	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—EGFR—pharynx cancer	1.1e-05	0.000119	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—TP53—pharynx cancer	1.09e-05	0.000119	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—EGFR—pharynx cancer	1.09e-05	0.000118	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—EGFR—pharynx cancer	1.09e-05	0.000118	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—EGFR—pharynx cancer	1.09e-05	0.000118	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—EGFR—pharynx cancer	1.08e-05	0.000117	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—B4GALT5—pharynx cancer	1.06e-05	0.000114	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—EGFR—pharynx cancer	1.05e-05	0.000114	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—TP53—pharynx cancer	1.05e-05	0.000114	CbGpPWpGaD
Bosutinib—HCK—Immune System—EGFR—pharynx cancer	1.05e-05	0.000113	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—EGFR—pharynx cancer	1.02e-05	0.000111	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—EGFR—pharynx cancer	1.02e-05	0.000111	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CDH1—pharynx cancer	1.02e-05	0.00011	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	1.01e-05	0.00011	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—EGFR—pharynx cancer	9.96e-06	0.000108	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CDH1—pharynx cancer	9.92e-06	0.000107	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—EGFR—pharynx cancer	9.85e-06	0.000107	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—EGFR—pharynx cancer	9.75e-06	0.000106	CbGpPWpGaD
Bosutinib—LYN—Immune System—CDH1—pharynx cancer	9.71e-06	0.000105	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—EGFR—pharynx cancer	9.71e-06	0.000105	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—EGFR—pharynx cancer	9.7e-06	0.000105	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CDH1—pharynx cancer	9.67e-06	0.000105	CbGpPWpGaD
Bosutinib—HCK—Disease—EGFR—pharynx cancer	9.65e-06	0.000105	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—EGFR—pharynx cancer	9.6e-06	0.000104	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—EGFR—pharynx cancer	9.57e-06	0.000104	CbGpPWpGaD
Bosutinib—FYN—Immune System—CDH1—pharynx cancer	9.56e-06	0.000104	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—EGFR—pharynx cancer	9.55e-06	0.000103	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CDH1—pharynx cancer	9.51e-06	0.000103	CbGpPWpGaD
Bosutinib—BLK—Immune System—EGFR—pharynx cancer	9.47e-06	0.000103	CbGpPWpGaD
Bosutinib—FGR—Immune System—EGFR—pharynx cancer	9.44e-06	0.000102	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—CCND1—pharynx cancer	9.39e-06	0.000102	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—EGFR—pharynx cancer	9.37e-06	0.000101	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—EGFR—pharynx cancer	9.29e-06	0.000101	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—EGFR—pharynx cancer	9.22e-06	9.99e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—TP53—pharynx cancer	9.17e-06	9.93e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—EGFR—pharynx cancer	9.12e-06	9.87e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—EGFR—pharynx cancer	9.12e-06	9.87e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—TP53—pharynx cancer	9.1e-06	9.85e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—EGFR—pharynx cancer	9.09e-06	9.85e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—TP53—pharynx cancer	9.05e-06	9.81e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—TP53—pharynx cancer	8.96e-06	9.7e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—EGFR—pharynx cancer	8.8e-06	9.54e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—EGFR—pharynx cancer	8.68e-06	9.4e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CNDP2—pharynx cancer	8.59e-06	9.3e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	8.51e-06	9.22e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CDH1—pharynx cancer	8.26e-06	8.95e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—CCND1—pharynx cancer	8.11e-06	8.79e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—EGFR—pharynx cancer	8.01e-06	8.68e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—EGFR—pharynx cancer	8.01e-06	8.68e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—CCND1—pharynx cancer	8e-06	8.66e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—EGFR—pharynx cancer	8e-06	8.66e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CDH1—pharynx cancer	7.96e-06	8.62e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—TP53—pharynx cancer	7.8e-06	8.45e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ADH7—pharynx cancer	7.77e-06	8.41e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—EGFR—pharynx cancer	7.73e-06	8.37e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—CCND1—pharynx cancer	7.7e-06	8.34e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—EGFR—pharynx cancer	7.68e-06	8.32e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—TP53—pharynx cancer	7.65e-06	8.29e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—TP53—pharynx cancer	7.65e-06	8.29e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—EGFR—pharynx cancer	7.62e-06	8.25e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TP53—pharynx cancer	7.46e-06	8.08e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—CCND1—pharynx cancer	7.42e-06	8.04e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—CCND1—pharynx cancer	7.42e-06	8.04e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TP53—pharynx cancer	7.39e-06	8.01e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—EGFR—pharynx cancer	7.37e-06	7.98e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—EGFR—pharynx cancer	7.23e-06	7.83e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—CCND1—pharynx cancer	7.15e-06	7.75e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—EGFR—pharynx cancer	7.08e-06	7.67e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CDH1—pharynx cancer	7.05e-06	7.64e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ADH1B—pharynx cancer	6.81e-06	7.38e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—EGFR—pharynx cancer	6.8e-06	7.37e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—EGFR—pharynx cancer	6.8e-06	7.36e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—pharynx cancer	6.6e-06	7.15e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—B4GALT5—pharynx cancer	6.51e-06	7.05e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—EGFR—pharynx cancer	6.51e-06	7.05e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CCND1—pharynx cancer	6.37e-06	6.9e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—EGFR—pharynx cancer	6.37e-06	6.89e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CCND1—pharynx cancer	6.28e-06	6.8e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—EGFR—pharynx cancer	6.27e-06	6.8e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—pharynx cancer	6.18e-06	6.7e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—EGFR—pharynx cancer	6.09e-06	6.59e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EGFR—pharynx cancer	6.04e-06	6.55e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CCND1—pharynx cancer	5.96e-06	6.45e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—EGFR—pharynx cancer	5.95e-06	6.44e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EGFR—pharynx cancer	5.82e-06	6.31e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EGFR—pharynx cancer	5.82e-06	6.31e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EGFR—pharynx cancer	5.8e-06	6.29e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—EGFR—pharynx cancer	5.68e-06	6.15e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EGFR—pharynx cancer	5.65e-06	6.12e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EGFR—pharynx cancer	5.61e-06	6.08e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CCND1—pharynx cancer	5.61e-06	6.07e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—EGFR—pharynx cancer	5.59e-06	6.06e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EGFR—pharynx cancer	5.56e-06	6.03e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EGFR—pharynx cancer	5.49e-06	5.95e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EGFR—pharynx cancer	5.36e-06	5.8e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—pharynx cancer	5.34e-06	5.79e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—pharynx cancer	5.27e-06	5.71e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—EGFR—pharynx cancer	5.16e-06	5.59e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EGFR—pharynx cancer	5.14e-06	5.56e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—pharynx cancer	5.07e-06	5.5e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—pharynx cancer	5e-06	5.41e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—pharynx cancer	4.93e-06	5.34e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCND1—pharynx cancer	4.9e-06	5.31e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—pharynx cancer	4.89e-06	5.29e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—pharynx cancer	4.89e-06	5.29e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCND1—pharynx cancer	4.78e-06	5.18e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—pharynx cancer	4.71e-06	5.1e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCND1—pharynx cancer	4.68e-06	5.07e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—pharynx cancer	4.67e-06	5.06e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—pharynx cancer	4.66e-06	5.04e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCND1—pharynx cancer	4.61e-06	4.99e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCND1—pharynx cancer	4.58e-06	4.97e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—pharynx cancer	4.4e-06	4.76e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—pharynx cancer	4.3e-06	4.66e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—pharynx cancer	4.19e-06	4.54e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—pharynx cancer	4.14e-06	4.48e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—pharynx cancer	4.12e-06	4.47e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—pharynx cancer	3.98e-06	4.31e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—pharynx cancer	3.92e-06	4.25e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—pharynx cancer	3.84e-06	4.16e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—pharynx cancer	3.84e-06	4.16e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—pharynx cancer	3.81e-06	4.12e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—pharynx cancer	3.75e-06	4.06e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—pharynx cancer	3.69e-06	4e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—pharynx cancer	3.67e-06	3.98e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—pharynx cancer	3.62e-06	3.92e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—pharynx cancer	3.6e-06	3.9e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—pharynx cancer	3.4e-06	3.68e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—pharynx cancer	3.23e-06	3.5e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—pharynx cancer	3.15e-06	3.41e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—pharynx cancer	3.08e-06	3.34e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—pharynx cancer	3.04e-06	3.29e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—pharynx cancer	3.02e-06	3.27e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—pharynx cancer	3.01e-06	3.26e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—pharynx cancer	2.67e-06	2.89e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—pharynx cancer	2.62e-06	2.84e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—pharynx cancer	2.53e-06	2.74e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—pharynx cancer	2.24e-06	2.42e-05	CbGpPWpGaD
